INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

EU Backs Earlier-Line Moves in Prostate and Kidney Cancer

Save Like Comments Compare coverage

Summary

CHMP backed Talzenna plus enzalutamide for earlier use in metastatic hormone-sensitive prostate cancer and Welireg plus lenvatinib for previously treated advanced renal cell carcinoma. Medscape News Europe

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    EU Backs Earlier-Line Moves in Prostate and Kidney Cancer

    CHMP backed Talzenna plus enzalutamide for earlier use in metastatic hormone-sensitive prostate cancer and Welireg plus lenvatinib for previously treated advanced renal cell carcinoma. Medscape News Europe

Comments

Comments need JavaScript.